Using a host immune classifier (HIC) test for patients with non-small cell lung cancer (NSCLC) may provide better predictors of treatment response and improve outcomes, according to research presented ...
Patients treated with immune checkpoint inhibitors had significantly different survival rates based on the test, regardless of PD ligand 1 classification. A blood-based proteomic test can help ...
BOULDER, Colo.--(BUSINESS WIRE)--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced new interim data published from the large ...
Prevalence of STK11, KEAP1, and KRAS mutations/co-mutations and associated clinical outcomes for patients newly diagnosed with metastatic non-small cell lung cancer. This is an ASCO Meeting Abstract ...
Impact of a pathologist-driven molecular testing protocol on veterans with non-small cell lung cancer. This is an ASCO Meeting Abstract from the 2023 ASCO Annual Meeting I. This abstract does not ...
(Singapore--4:45 p.m. SPT/3:45 a.m. EST January 30, 2021--Using a host immune classifier (HIC) test for patients with non-small cell lung cancer (NSCLC) may provide better predictors of treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results